Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial to Evaluate Single Dose Versus Three Doses of Stereotactic Radiation Therapy (SBRT) Prior to Surgery for Early Stage Breast Carcinoma: SIGNAL 2.0 (Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy) Trial

NCT02212860 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

NCT NCT02212860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02212860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial to Evaluate Single Dose Versus Three Doses of Stereotactic Radiation Therapy (SBRT) Prior to Surgery for Early Stage Breast Carcinoma: SIGNAL 2.0 (Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy) Trial
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Not applicable
Overall status
Completed
Start date
April 27, 2015
Completion date
April 30, 2024
Enrollment
139 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early stage breast carcinoma